INVASCENT
InvAscent is the investment advisor to EILSF (Fund I), India Life Sciences Fund II (ILSF-II) and India Life Sciences Fund III (ILSF-III). These funds provide private equity growth capital to companies in the Indian pharmaceutical, healthcare, animal health and medtech industries. Examples of funds usage include capacity expansion, introduction of new products, acquisitions, etc. The typical investment size is in the range of USD 10 - 40 million over the life of the investment for a significant minority stake.
INVASCENT
Industry:
Health Care Pharmaceutical
Status:
Active
Contact:
040 2354 1305
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Font Awesome Apache Euro
Similar Organizations
1315 Capital
1315 Capital provides expansion and growth capital to commercial stage pharmaceuticals, medical technologies, and healthcare services.
Rittenhouse Ventures
Rittenhouse Ventures invests in small rounds of capital-efficient Early-Growth stage companies primarily in Healthcare and Pharma IT.
Tivorsan Pharmaceuticals
Tivorsan Pharmaceuticals is a protein therapeutics company that focuses on treating neuromuscular disorders.
Current Employees Featured
Vishy Chebrol Co-Founder, Chief Investment Officer and Managing Director @ InvAscent
Co-Founder, Chief Investment Officer and Managing Director
2017-07-01
T.P. Devarajan Managing Director @ InvAscent
Managing Director
Hari Buggana Founder, Chairman and Managing Director @ InvAscent
Founder, Chairman and Managing Director
2017-06-01
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-06-02 | Accumax | InvAscent investment in Private Equity Round - Accumax | 5.2 B INR |
| 2022-04-25 | Malladi Drugs | InvAscent investment in Private Equity Round - Malladi Drugs | 2.5 B INR |
| 2021-02-02 | MediBuddy | InvAscent investment in Series B - MediBuddy | 40 M USD |
| 2020-06-16 | Murli Krishna Pharma | InvAscent investment in Private Equity Round - Murli Krishna Pharma | 700 M INR |
| 2020-06-08 | Sharp Sight | InvAscent investment in Private Equity Round - Sharp Sight | 700 M INR |
| 2019-01-01 | Intron Life Sciences | InvAscent investment in Private Equity Round - Intron Life Sciences | 10 M USD |
| 2018-10-31 | Strides Pharma Science | InvAscent investment in Post-IPO Equity - Strides Pharma Science | 20 M USD |
| 2017-03-15 | Oliva Clinic | InvAscent investment in Series A - Oliva Clinic | 832 K USD |
| 2016-12-01 | Stericon Pharma | InvAscent investment in Private Equity Round - Stericon Pharma | 500 M INR |
| 2016-01-08 | Sandor | InvAscent investment in Seed Round - Sandor | 8.98 M USD |
More informations about "InvAscent"
About Us - InvAscent
InvAscent has a successful track record of partnering with entrepreneurs in the Indian pharma, healthcare delivery, medtech, and animal health industries, enabling creation of market …See details»
InvAscent - Crunchbase Investor Profile & Investments
InvAscent is a private equity growth capital for pharma, healthcare, animal health, and medtech businesses in India. InvAscent may be growing as it has recently …See details»
invascent.com Reviews: Is this site a scam or legit? - Scam Detector
Organization Domains By Proxy, LLC . Owner Registration Private . Address DomainsByProxy.com 2155 E Warner Rd . State Arizona . Country UNITED STATES . …See details»
InvAscent - Investments, Portfolio & Company Exits - Crunchbase
InvAscent 's most notable exits include MediBuddy, Inventia Healthcare, and Synergia Life Sciences. Which industries has this organization had the most exits in? Show . MediBuddy …See details»
Press Releases - InvAscent
Founded in 2005, InvAscent is the investment advisor to a family of funds that operate under the name “India Life Sciences Fund” or ILSF.See details»
InvAscent - Funding, Financials, Valuation & Investors - Crunchbase
InvAscent . Connect to CRM . Save . Summary. Financials. Investments. People. Technology. Signals & News. Similar Companies. Highlights. Funds 1. Funding. InvAscent has raised a …See details»
InvAscent on LinkedIn: #healthcare #ventureintelligence #investor …
InvAscent receives the Healthcare Investor of the Year 2022 Award as part of Venture Intelligence APEX‘23 Private Equity & Venture Capital awards event in Mumbai.See details»
India Life Sciences Fund IV: Performance | PitchBook
May 1, 2024 India Life Sciences Fund IV is a 2023 vintage private equity growth expansion fund managed by InvAscent. The fund is located in Telangana, India and invests India. The fund …See details»
Team - InvAscent
Prior to joining InvAscent, Anil spent four years working as a Principal Consultant at Pricewaterhouse Coopers Private Limited, an international financial services company. During his time there, he was responsible for performing due …See details»
InvAscent - Contacts, Employees, Board Members, Advisors
InvAscent has 3 current employee profiles, including Co-Founder, Chief Investment Officer and Managing Director Vishy Chebrol. Contacts. Edit Contacts Section. Job Department. Protected …See details»
InvAscent Closes India Life Sciences Fund III at US$250 Million ...
Jan 31, 2019 An independent, non-profit organization, the association brings together 300+ firms—including institutional investors, fund managers, and industry advisors—who manage …See details»
Portfolio – InvAscent
Plot No. 1174A, Road No. 56, Jubilee Hills, Hyderabad, Telangana, India – 500033 Tel: +91 (40) 23541305 Email: info@invascent.comSee details»
InvAscent joins race to buy stake in PE-backed hospital chain
Jul 30, 2024 Healthcare-focused private equity firm InvAscent, which has already struck three bets this year, is among a clutch of institutional investors that are in the fray to acquire stake in …See details»
InvAscent crosses halfway mark for new healthcare fund, eyes
Jun 26, 2024 Hari Buggana, founder, chairman and managing director, InvAscent Healthcare-focused private equity firm InvAscent, which has already struck three bets so far this year, is …See details»
Motilal Oswal and InvAscent Invest US$100 Million in Symbiotec ...
Dec 18, 2018 An independent, non-profit organization, the association brings together 300+ firms—including institutional investors, fund managers, and industry advisors—who manage …See details»
Hari Buggana - Founder, Chairman and Managing Director
Hari Buggana is the Founder and Chairman of InvAscent. He Previously worked at McKinsey & Co. as a Consultant. Hari Buggana attended Northwestern University - Kellogg School of …See details»
InvAscent invests in Maiva Pharma
May 2, 2024. InvAscent, through India Life Sciences IV (ILSF IV), in partnership Morgan Stanley Private Equity Asia, has invested INR 10,000 Mn in Maiva Pharma, India’s 2 nd largest pure …See details»
InvAscent hits first close for new healthcare fund; strikes back-to ...
Dec 18, 2023 Homegrown healthcare-focussed private equity firm InvAscent has hit the first close for its latest fund, even as it struck a fresh investment in an active pharmaceutical …See details»
InvAscent invests in Fleming Laboratories
Dec 20, 2023 InvAscent is the investment advisor to a family of funds that operate under the name “India Life Sciences Fund” or ILSF. It has so far raised ~ USD 500 Mn from global …See details»